Evidence-Based Medicine and Real-World Data in Allergen Immunotherapy Today and in the Future: Quality or Quantity?

Purpose of the review Data obtained from controlled clinical trials remains the gold standard for the evaluation of treatment efficacy and safety. This information is used in systematic reviews and meta-analysis providing data for evidence-based medicine (EBM) statements and conclusions which are preferred by regulatory and academic groups when decisions and recommendations need to be given. Recent findings: The quantity and diversity of real-world data (RWD) have been increasing exponentially as technology and integrated electronic medical records have made this information increasingly accessible and useful for outcomes research and regulatory purposes. There are increasing interest and potential for converting RWD into real-world evidence that, through careful analysis and interpretation, can be used to inform healthcare decision-making. Summary In this article, we present a concise summary of the literature about the role of EBM and RWD in allergen immunotherapy. We are aiming to evaluate their influence on current and future decisions for good clinical practice parameter recommendations.